Overview

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2021-04-13
Target enrollment:
Participant gender:
Summary
Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Salarius Pharmaceuticals, LLC